PL EN


Preferences help
enabled [disable] Abstract
Number of results
2010 | 10 | 3 | 145-151
Article title

Fingolimod w leczeniu stwardnienia rozsianego

Content
Title variants
EN
Fingolimod in treatment of multiple sclerosis
Languages of publication
EN PL
Abstracts
EN
Currently immunomodulatory drugs for multiple sclerosis (MS) are injected subcutaneously, intramuscularly or intravenously. This route of drug delivery creates some inconveniences for patients and health care system and there is a need to introduce oral treatment with efficacy superior to available treatments. The first drug of this characteristics is fingolimod (FTY720). This drug is easily absorbed from digestive tract with the maximal concentration in the blood 12-16 hours after ingestion. The mechanism of FTY720 action targets sequestration of mature lymphocytes in lymph nodes and Peyer’s patch, what limits the number of lymphocytes in the blood and inflammatory cuffs. The function of lymphocytes and their activation is not affected. It is suggested that fingolimod slows lymphocyte migration using two independent mechanisms: firstly by diminishing the number of S1P1 receptors on lymphocytes and blocking signalling for their migration, the second mechanism relies on constant stimulation of those receptors on endothelium in lymph node sinuses to strengthen the barrier limiting lymphocyte migration. Promising results of phase II clinical trials enabled development of two big phase III trials which opened the way to register fingolimod: FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) and TRANSFORMS (Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis). FREEDOMS study confirmed superiority of fingolimod over placebo in all analyzed endpoints. TRANSFORMS study showed that fingolimod slows MS activity stronger that interferon β-1a. Those data confirm that FTY720 is promising new drug for the treatment of MS.
PL
W chwili obecnej leczenie immunomodulujące stwardnienia rozsianego (łac. sclerosis multiplex, SM) polega na podawaniu leków w postaci iniekcji podskórnych, domięśniowych bądź dożylnych. Powoduje to liczne niedogodności dla pacjentów, wobec czego istnieje zapotrzebowanie na wprowadzenie leku doustnego o skuteczności przewyższającej skuteczność leków obecnie stosowanych. Pierwszym tego typu lekiem jest fingolimod (FTY720). Lek ten dobrze wchłania się z przewodu pokarmowego, a maksymalne stężenie we krwi osiąga po 12-16 godzinach od podania. Mechanizm działania fingolimodu polega na powodowaniu sekwestracji dojrzałych limfocytów w węzłach chłonnych i kępkach Peyera, co zmniejsza ich liczbę we krwi oraz w naciekach limfocytarnych. FTY720 nie upośledza funkcji limfocytów, a zwłaszcza aktywacji limfocytów T. Uważa się, że fingolimod może hamować migrację limfocytów na drodze dwóch niezależnych mechanizmów: pierwszy to zmniejszanie liczby receptorów S1P1 na limfocytach T i osłabienie sygnału do ich migracji, drugi to stałe pobudzanie tych receptorów obecnych na śródbłonku zatok w węzłach chłonnych do wzmacniania bariery ograniczającej migrację limfocytów. Zachęcające wyniki badań klinicznych II fazy umożliwiły zaprojektowanie dwóch dużych badań III fazy, które otworzyły fingolimodowi drogę do rejestracji: FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) i TRANSFORMS (Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing- Remitting Multiple Sclerosis). W zakresie wszystkich klinicznych i rezonansowych punktów końcowych w badaniu FREEDOMS udowodniono przewagę fingolimodu nad placebo. Badanie TRANSFORMS pozwoliło udowodnić, że fingolimod zmniejsza aktywność SM skuteczniej niż interferon β-1a. Dane te potwierdzają, że fingolimod jest obiecującym nowym lekiem w terapii SM.
Discipline
Publisher

Year
Volume
10
Issue
3
Pages
145-151
Physical description
Contributors
  • Oddział Kliniczny Propedeutyki Neurologicznej, Uniwersytet Medyczny w Łodzi
  • Oddział Kliniczny Propedeutyki Neurologicznej, Uniwersytet Medyczny w Łodzi
  • Oddział Kliniczny Propedeutyki Neurologicznej, Uniwersytet Medyczny w Łodzi, WSS im. M. Kopernika, ul. Pabianicka 62, 93-513 Łódź, tel.: 42 689 53 60, aglabinski@gmail.com
References
  • 1. Adachi K., Chiba K.: FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect. Medicin. Chem. 2007; 1: 11-23.
  • 2. Chiba K., Kataoka H., Seki N. i wsp.: Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Int. Immunopharmacol. 2010 Oct 16. [Epub ahead of print].
  • 3. Schreiber S.L.: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283-287.
  • 4. Schreiber S.L.: Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell 1992; 70: 365-368.
  • 5. Kiuchi M., Adachi K., Kohara T. i wsp.: Synthesis and immunosuppressive activity of 2-substituted 2-aminopro-pane-1,3-diols and 2-aminoethanols. J. Med. Chem. 2000: 43: 2946-2961.
  • 6. Kiuchi M., Adachi K., Kohara T. i wsp.: Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. Bioorg. Med. Chem. Lett. 1998; 8: 101-106.
  • 7. Kiuchi M., Adachi K., Tomatsu A. i wsp.: Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. Bioorg. Med. Chem. 2005; 13: 425-432.
  • 8. Chiba K., Hoshino Y., Suzuki C. i wsp.: FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant. Proc. 1996; 28: 1056-1059.
  • 9. Masubuchi Y., Kawaguchi T., Ohtsuki M. i wsp.: FTY720, a novel immunosuppressant, possessing unique mechanisms. IV Prevention of graft versus host reactions in rats. Transplant. Proc. 1996; 28: 1064-1065.
  • 10. Chiba K., Yanagawa Y., Masubuchi Y. i wsp.: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 1998; 160: 5037-5044.
  • 11. Yanagawa Y., Masubuchi Y., Chiba K.: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer’s patches by FTY720-induced lymphocyte homing. Immunology 1998; 95: 591-594.
  • 12. Fujita T., Hirose R., Yoneta M. i wsp.: Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols. J. Med. Chem. 1996; 39: 4451-4459.
  • 13. Brinkmann V, Davis M.D., Heise C.E. i wsp.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 2002; 277: 21453-21457.
  • 14. Mandala S., Hajdu R., Bergstrom J. i wsp.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
  • 15. Paugh S.W, Payne S.G., Barbour S.E. i wsp.: The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 2003; 554: 189-193.
  • 16. Brinkmann V, Lynch K.R.: FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 2002; 14: 569-575.
  • 17. Matloubian M., Lo C.G., Cinamon G. i wsp.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
  • 18. Lo C.G., Xu Y., Proia R.L., Cyster J.G.: Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J. Exp. Med. 2005; 201: 291-301.
  • 19. Sanna M.G., Wang S.K., Gonzalez-Cabrera PJ. i wsp.: Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1PX antagonist in vivo. Nat. Chem. Biol. 2006; 2: 434-441.
  • 20. Jo E., Sanna M.G., Gonzalez-Cabrera PJ. i wsp.: S1Pj-selec-tive in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 2005; 12: 703-715.
  • 21. Baumruker T., Billich A., Brinkmann V: FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin. Investig. Drugs 2007; 16: 283-289.
  • 22. Maki T., Gottschalk R., Monaco A.P.: Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 2002; 74: 1684-1686.
  • 23. Mizushima T., Ito T., Kishi D. i wsp.: Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm. Bowel Dis. 2004; 10: 182-192.
  • 24. Fujino M., Funeshima N., Kitazawa Y. i wsp.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 2003; 305: 70-77.
  • 25. Kataoka H., Sugahara K., Shimano K. i wsp.: FTY720, sphin-gosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2005; 2: 439-448.
  • 26. Lan Y.Y., De Creus A., Colvin B.L. i wsp.: The sphin-gosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am. J. Transplant. 2005; 5: 2649-2659.
  • 27. Müller H., Hofer S., Kaneider N. i wsp.: The immunomod-ulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur. J. Immunol. 2005; 35: 533-545.
  • 28. Payne S.G., Oskeritzian C.A., Griffiths R. i wsp.: The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 2007; 109: 1077-1085.
  • 29. Fragoso G., Martínez-Bermúdez A.K., Liu H.N. i wsp.: Developmental differences in H2O2-induced oligodendrocyte cell death: role of glutathione, mitogen-activated protein kinases and caspase 3. J. Neurochem. 2004; 90: 392-404.
  • 30. Saini H.S., Coelho R.P., Goparaju S.K. i wsp.: Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J. Neurochem. 2005; 95: 1298-1310.
  • 31. Cui Q.L., Fogle E., Almazan G.: Muscarinic acetylcholine receptors mediate oligodendrocyte progenitor survival through Src-like tyrosine kinases and PI3K/Akt pathways. Neurochem. Int. 2006; 48: 383-393.
  • 32. Kappos L., Antel J., Comi G. i wsp.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006; 355: 1124-1140.
  • 33. Montalban X., O’Connor P., Antel J. i wsp.: Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four-year results from a phase II extension. ECTRIMS, Göteborg, 2010. P06.128
  • 34. Kappos L., Radue E.W, O’Connor P. i wsp.; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010; 362: 387-401.
  • 35. Cohen J.A., Barkhof F., Comi G. i wsp.; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010; 362: 402-415.
  • 36. Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis (FREEDOMS II). Adres: http://www.clinicaltrials.gov/ct2/show/NCT00355134.
  • 37. FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS). Adres: http://www.clinicaltrials.gov/ct2/ show/NCT00731692?term=fingolimod&rank=8.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-26aad200-b627-4b58-861c-eb057049b2dd
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.